Skip to main content
Top
Published in: Drugs 3/2017

01-03-2017 | Therapy in Practice

Drug Therapy for Stable Angina Pectoris

Authors: Talla A. Rousan, Sunil T. Mathew, Udho Thadani

Published in: Drugs | Issue 3/2017

Login to get access

Abstract

Chronic stable angina pectoris refers to the predictable, reproducible occurrence of pressure or a choking sensation in the chest or adjacent areas caused by myocardial ischemia in association with physical or emotional stress, and cessation of exertion and or sublingual nitroglycerin invariably relieves the discomfort. It is a common presenting symptom of severe narrowing of one or more coronary arteries, non-obstructive coronary arteries, or even when the coronary arteries are angiographically normal. Patients often avoid activities which precipitate symptoms and have impaired quality of life. Most patients with angina pectoris can be managed with lifestyle changes, especially abstinence from smoking and regular exercise, and anti-anginal drugs. However, the choice of initial or combination antianginals as recommended in the guidelines is not evidence based. In addition, patients with stable angina due to coronary artery disease should also receive aspirin and a statin. Treatment of patients with angina and normal coronary arteries remains to be established. The aim of this article is to provide the readers not only with a guideline-based approach, which varies from one country to another, but also an individual-based approach, which takes into consideration circulatory status and the presence or absence of comorbidities in the treatment decision-making process. This manuscript primarily deals with drug therapy of stable angina pectoris and not coronary artery revascularization, which also provides angina relief but is usually reserved for patients who fail to respond to adequate drug therapy.
Literature
1.
go back to reference Heberden W. Some account of a disorder of the breast. Medical Tranasactions. Vol. 2. Royal College of Physicians. 1772. Heberden W. Some account of a disorder of the breast. Medical Tranasactions. Vol. 2. Royal College of Physicians. 1772.
2.
go back to reference Opie LH. Angina pectoris: the evolution of concepts. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S3–9.PubMedCrossRef Opie LH. Angina pectoris: the evolution of concepts. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S3–9.PubMedCrossRef
4.
go back to reference Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S11–29 (quiz S98–9). Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S11–29 (quiz S98–9).
5.
go back to reference Lucien C. Grading of angina pectoris. Circulation. 1976;54:522–3. Lucien C. Grading of angina pectoris. Circulation. 1976;54:522–3.
6.
go back to reference Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164. doi:10.1016/j.jacc.2012.07.013.PubMedCrossRef Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164. doi:10.​1016/​j.​jacc.​2012.​07.​013.PubMedCrossRef
7.
go back to reference Thadani U. Management of stable angina-current guidelines: a critical apraisal. Cardiovasc Drugs Ther. 2016;30(4):419–26.PubMedCrossRef Thadani U. Management of stable angina-current guidelines: a critical apraisal. Cardiovasc Drugs Ther. 2016;30(4):419–26.PubMedCrossRef
8.
go back to reference Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296.CrossRef Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi:10.​1093/​eurheartj/​eht296.CrossRef
10.
go back to reference Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases. Bethesda: National Heart, Lung, and Blood Institute; 2006. Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases. Bethesda: National Heart, Lung, and Blood Institute; 2006.
11.
go back to reference Javitz HS, Ward MM, Watson JB, Jaana M. Cost of illness of chronic angina. Am J Manag Care. 2004;10(11 Suppl):S358–69.PubMed Javitz HS, Ward MM, Watson JB, Jaana M. Cost of illness of chronic angina. Am J Manag Care. 2004;10(11 Suppl):S358–69.PubMed
12.
go back to reference Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol. 2000;35(4):907–14.PubMedCrossRef Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol. 2000;35(4):907–14.PubMedCrossRef
13.
go back to reference Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1997;336(2):92–9. doi:10.1056/NEJM199701093360203.PubMedCrossRef Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1997;336(2):92–9. doi:10.​1056/​NEJM199701093360​203.PubMedCrossRef
14.
go back to reference Thadani U. Chronic stable angina pectoris. In: M. C, editor. Cardiology. Philadelphia: Saunders Elsevier; 2010. p. 283–99. Thadani U. Chronic stable angina pectoris. In: M. C, editor. Cardiology. Philadelphia: Saunders Elsevier; 2010. p. 283–99.
16.
go back to reference Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina–the VASCO-angina study. Int J Cardiol. 2013;168(2):1078–81. doi:10.1016/j.ijcard.2012.11.001.PubMedCrossRef Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina–the VASCO-angina study. Int J Cardiol. 2013;168(2):1078–81. doi:10.​1016/​j.​ijcard.​2012.​11.​001.PubMedCrossRef
17.
go back to reference Sendon JL, Lee S, Cheng ML, Ben-Yehuda O, investigators Cs. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012;19(5):952–9. doi:10.1177/2047487312450133. Sendon JL, Lee S, Cheng ML, Ben-Yehuda O, investigators Cs. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012;19(5):952–9. doi:10.​1177/​2047487312450133​.
18.
19.
go back to reference McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58(1):143–57.PubMedCrossRef McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58(1):143–57.PubMedCrossRef
21.
23.
go back to reference Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):611–23.PubMedCrossRef Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):611–23.PubMedCrossRef
24.
go back to reference Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):625–33.PubMedCrossRef Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther. 1994;8(4):625–33.PubMedCrossRef
25.
go back to reference Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927–36.PubMedCrossRef Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927–36.PubMedCrossRef
26.
go back to reference Thadani U, Opie, LH. Nitrates. In: Opie, LH, editor. Drugs for the heart. Philadelphia: W. B. Saunders; 1995. p. 31-49. Thadani U, Opie, LH. Nitrates. In: Opie, LH, editor. Drugs for the heart. Philadelphia: W. B. Saunders; 1995. p. 31-49.
30.
go back to reference Thadani U, Wittig T. A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina. Clin Med Insights Cardiol. 2012;6:87–95. doi:10.4137/CMC.S9132.PubMedPubMedCentralCrossRef Thadani U, Wittig T. A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina. Clin Med Insights Cardiol. 2012;6:87–95. doi:10.​4137/​CMC.​S9132.PubMedPubMedCentralCrossRef
31.
go back to reference Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49(2):411–9.PubMedCrossRef Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49(2):411–9.PubMedCrossRef
32.
go back to reference Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16(4):936–40.PubMedCrossRef Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16(4):936–40.PubMedCrossRef
33.
go back to reference Fox KM, Dargie HJ, Deanfield J, Maseri A. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. The Transdermal Nitrate Investigators. Br Heart J. 1991;66(2):151–5.PubMedPubMedCentralCrossRef Fox KM, Dargie HJ, Deanfield J, Maseri A. Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. The Transdermal Nitrate Investigators. Br Heart J. 1991;66(2):151–5.PubMedPubMedCentralCrossRef
34.
go back to reference Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol. 1991;68(13):1263–73. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol. 1991;68(13):1263–73.
35.
go back to reference Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72(17):1249–56.PubMedCrossRef Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72(17):1249–56.PubMedCrossRef
38.
go back to reference Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(9A):9M–18M.PubMedCrossRef Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(9A):9M–18M.PubMedCrossRef
39.
go back to reference Prichard BN, Owens CW. Mode of action of beta-adrenergic blocking drugs in hypertension. Clin Physiol Biochem. 1990;8(Suppl 2):1–10.PubMed Prichard BN, Owens CW. Mode of action of beta-adrenergic blocking drugs in hypertension. Clin Physiol Biochem. 1990;8(Suppl 2):1–10.PubMed
40.
41.
42.
go back to reference Thadani U, Davidson C, Singleton W, Taylor SH. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980;68(2):243–50.PubMedCrossRef Thadani U, Davidson C, Singleton W, Taylor SH. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980;68(2):243–50.PubMedCrossRef
43.
go back to reference Thadani U, Sharma B, Meeran MK, Majid PA, Whitaker W, Taylor SH. Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973;1(5846):138–42.PubMedPubMedCentralCrossRef Thadani U, Sharma B, Meeran MK, Majid PA, Whitaker W, Taylor SH. Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973;1(5846):138–42.PubMedPubMedCentralCrossRef
44.
go back to reference Opie LH, Sonnenblick EH, Frishman W, Thadani U. Beta blockers. Drugs for the heart. Philadelphia: W.B. Saunders; 1995, p. 1–27. Opie LH, Sonnenblick EH, Frishman W, Thadani U. Beta blockers. Drugs for the heart. Philadelphia: W.B. Saunders; 1995, p. 1–27.
45.
go back to reference Cruickshank JM. Measurement and cardiovascular relevance of partial agonist activity (PAA) involving beta 1- and beta 2-adrenoceptors. Pharmacol Ther. 1990;46(2):199–242.PubMedCrossRef Cruickshank JM. Measurement and cardiovascular relevance of partial agonist activity (PAA) involving beta 1- and beta 2-adrenoceptors. Pharmacol Ther. 1990;46(2):199–242.PubMedCrossRef
46.
go back to reference McDevitt DG. Clinical significance of cardioselectivity state-of-the-art. Drugs. 1983;25(Supplemental 2):219–26. McDevitt DG. Clinical significance of cardioselectivity state-of-the-art. Drugs. 1983;25(Supplemental 2):219–26.
47.
go back to reference Prichard BN. Beta-blocking agents with vasodilating action. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S1–4.PubMedCrossRef Prichard BN. Beta-blocking agents with vasodilating action. J Cardiovasc Pharmacol. 1992;19(Suppl 1):S1–4.PubMedCrossRef
49.
go back to reference CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
50.
go back to reference MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.
51.
go back to reference Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55. doi:10.1056/NEJM199605233342101.PubMedCrossRef Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55. doi:10.​1056/​NEJM199605233342​101.PubMedCrossRef
52.
go back to reference Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA. 1981;246(18):2073–4. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA. 1981;246(18):2073–4.
53.
go back to reference Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–32. Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–32.
54.
go back to reference Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):872–81. doi:10.1161/CIRCOUTCOMES.114.001073.PubMedCrossRef Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):872–81. doi:10.​1161/​CIRCOUTCOMES.​114.​001073.PubMedCrossRef
57.
go back to reference Thadani U. Assessment of “optimal” beta blockade in treating patients with angina pectoris. Acta Med Scand Suppl. 1985;694:178–87.PubMed Thadani U. Assessment of “optimal” beta blockade in treating patients with angina pectoris. Acta Med Scand Suppl. 1985;694:178–87.PubMed
58.
go back to reference Goodman & Gilman’s Pharmacological Basis of Therapeutics. Brunton L, Chabner B, Knollmann B, Editors. 12th ed. New York: McGraw-Hill; 2011 Goodman & Gilman’s Pharmacological Basis of Therapeutics. Brunton L, Chabner B, Knollmann B, Editors. 12th ed. New York: McGraw-Hill; 2011
59.
go back to reference Cordero A, Bertomeu-Gonzalez V, Mazon P, Moreno-Arribas J, Facila L, Bueno H, et al. Differential effect of beta-blockers for heart rate control in coronary artery disease. Clin Cardiol. 2011;34(12):748–54. doi:10.1002/clc.20981.PubMedCrossRef Cordero A, Bertomeu-Gonzalez V, Mazon P, Moreno-Arribas J, Facila L, Bueno H, et al. Differential effect of beta-blockers for heart rate control in coronary artery disease. Clin Cardiol. 2011;34(12):748–54. doi:10.​1002/​clc.​20981.PubMedCrossRef
60.
go back to reference Greenblatt DJK-WJ. Clinical toxicity of propranolol and practolol: a report from the Boston Collaborative Drug Surveillance Program. Cardiovascualr drugs. Sydney: Adis Press; 1977. Greenblatt DJK-WJ. Clinical toxicity of propranolol and practolol: a report from the Boston Collaborative Drug Surveillance Program. Cardiovascualr drugs. Sydney: Adis Press; 1977.
61.
go back to reference Opie LH, Gersh BJ. Drugs for the heart. 8th ed. Philadelphia: Elsevier Saunders; 2013. Opie LH, Gersh BJ. Drugs for the heart. 8th ed. Philadelphia: Elsevier Saunders; 2013.
64.
go back to reference Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Probl Cardiol. 1999;24(5):236–340.PubMedCrossRef Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Probl Cardiol. 1999;24(5):236–340.PubMedCrossRef
65.
go back to reference Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. Drugs. 1978;15(3):169–97.PubMedCrossRef Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. Drugs. 1978;15(3):169–97.PubMedCrossRef
66.
go back to reference Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387–454.PubMedCrossRef Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387–454.PubMedCrossRef
67.
go back to reference Ezekowitz MD, Hossack K, Mehta JL, Thadani U, Weidler DJ, Kostuk W, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129(3):527–35.PubMedCrossRef Ezekowitz MD, Hossack K, Mehta JL, Thadani U, Weidler DJ, Kostuk W, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129(3):527–35.PubMedCrossRef
68.
go back to reference Glasser SP, West TW. Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol. 1988;62(9):518–22.PubMedCrossRef Glasser SP, West TW. Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. Am J Cardiol. 1988;62(9):518–22.PubMedCrossRef
69.
go back to reference Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol. 1994;74(1):9–17.PubMedCrossRef Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol. 1994;74(1):9–17.PubMedCrossRef
70.
go back to reference Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. Cardiologia. 1995;40(12 Suppl 1):301. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. Cardiologia. 1995;40(12 Suppl 1):301.
71.
go back to reference Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O’Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol. 1997;52(2):95–100.PubMedCrossRef Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O’Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol. 1997;52(2):95–100.PubMedCrossRef
72.
go back to reference Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849–57. doi:10.1016/S0140-6736(04)16980-8.PubMedCrossRef Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849–57. doi:10.​1016/​S0140-6736(04)16980-8.PubMedCrossRef
74.
go back to reference Van Der Vring JA, Daniels MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, et al. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN). Br J Clin Pharmacol. 1999;47(5):493–8. Van Der Vring JA, Daniels MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, et al. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN). Br J Clin Pharmacol. 1999;47(5):493–8.
76.
go back to reference Pepine CJ, Feldman RL, Whittle J, Curry RC, Conti CR. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J. 1981;101(6):719–25.PubMedCrossRef Pepine CJ, Feldman RL, Whittle J, Curry RC, Conti CR. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. Am Heart J. 1981;101(6):719–25.PubMedCrossRef
77.
go back to reference The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385–92. doi:10.1056/NEJM198808183190701. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385–92. doi:10.​1056/​NEJM198808183190​701.
78.
go back to reference Krebs R. Adverse reactions with calcium antagonists. Hypertension. 1983;5(4 Pt 2):II125–9. Krebs R. Adverse reactions with calcium antagonists. Hypertension. 1983;5(4 Pt 2):II125–9.
79.
go back to reference Nicorandil for angina. Drug Ther Bull. 1995;33(12):89–92. Nicorandil for angina. Drug Ther Bull. 1995;33(12):89–92.
80.
go back to reference Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 1989;63(21):61J–5J.PubMedCrossRef Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 1989;63(21):61J–5J.PubMedCrossRef
82.
84.
go back to reference Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.PubMedCrossRef Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.PubMedCrossRef
85.
go back to reference Ferrari R, Ceconi C. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2011;9(8):959–73. doi:10.1586/erc.11.99.PubMedCrossRef Ferrari R, Ceconi C. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2011;9(8):959–73. doi:10.​1586/​erc.​11.​99.PubMedCrossRef
86.
87.
go back to reference Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–37. doi:10.1111/j.1365-2125.2005.02544.x.PubMedCrossRef Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–37. doi:10.​1111/​j.​1365-2125.​2005.​02544.​x.PubMedCrossRef
88.
go back to reference Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Investigators I. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36. doi:10.1093/eurheartj/ehi586.PubMedCrossRef Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Investigators I. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36. doi:10.​1093/​eurheartj/​ehi586.PubMedCrossRef
89.
90.
go back to reference Werdan K, Ebelt H, Nuding S, Hopfner F, Hack G, Muller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365–73. doi:10.1007/s00392-011-0402-4.PubMedCrossRef Werdan K, Ebelt H, Nuding S, Hopfner F, Hack G, Muller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365–73. doi:10.​1007/​s00392-011-0402-4.PubMedCrossRef
92.
go back to reference Muller-Werdan U, Stockl G, Ebelt H, Nuding S, Hopfner F, Werdan K, et al. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34–41. doi:10.1016/j.exger.2014.09.002.PubMedCrossRef Muller-Werdan U, Stockl G, Ebelt H, Nuding S, Hopfner F, Werdan K, et al. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34–41. doi:10.​1016/​j.​exger.​2014.​09.​002.PubMedCrossRef
93.
go back to reference Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16. doi:10.1016/S0140-6736(08)61170-8.PubMedCrossRef Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16. doi:10.​1016/​S0140-6736(08)61170-8.PubMedCrossRef
94.
go back to reference Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337–45. doi:10.1093/eurheartj/ehp358.PubMedCrossRef Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337–45. doi:10.​1093/​eurheartj/​ehp358.PubMedCrossRef
95.
97.
go back to reference Amgen, Inc. Ivabradine: highlights of prescribing information. 2015. Amgen, Inc. Ivabradine: highlights of prescribing information. 2015.
98.
go back to reference Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131–8.PubMed Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131–8.PubMed
99.
go back to reference Anderson JR, Khou S, Nawarskas JJ. Ranolazine: a potential new treatment for chronic stable angina. Heart Dis. 2001;3(4):263–9.PubMedCrossRef Anderson JR, Khou S, Nawarskas JJ. Ranolazine: a potential new treatment for chronic stable angina. Heart Dis. 2001;3(4):263–9.PubMedCrossRef
100.
go back to reference Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart (British Cardiac Society). 2006;92 Suppl 4:iv6–14. doi:10.1136/hrt.2005.078790. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart (British Cardiac Society). 2006;92 Suppl 4:iv6–14. doi:10.​1136/​hrt.​2005.​078790.
101.
go back to reference Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012;13(17):2555–63. doi:10.1517/14656566.2012.740458.PubMedCrossRef Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012;13(17):2555–63. doi:10.​1517/​14656566.​2012.​740458.PubMedCrossRef
103.
go back to reference Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994;90(2):726–34.PubMedCrossRef Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994;90(2):726–34.PubMedCrossRef
104.
go back to reference Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999;84(1):46–50. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999;84(1):46–50.
105.
go back to reference Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16. doi:10.1001/jama.291.3.309.PubMedCrossRef Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16. doi:10.​1001/​jama.​291.​3.​309.PubMedCrossRef
106.
go back to reference Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038–45. doi:10.1016/j.jacc.2013.02.011.PubMedCrossRef Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038–45. doi:10.​1016/​j.​jacc.​2013.​02.​011.PubMedCrossRef
107.
go back to reference Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, Investigators E. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–75. doi:10.1016/j.jacc.2006.05.044.PubMedCrossRef Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, Investigators E. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–75. doi:10.​1016/​j.​jacc.​2006.​05.​044.PubMedCrossRef
108.
go back to reference Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83. doi:10.1001/jama.297.16.1775.PubMedCrossRef Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83. doi:10.​1001/​jama.​297.​16.​1775.PubMedCrossRef
109.
go back to reference Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37(19):1504–13. doi:10.1093/eurheartj/ehv647.PubMedCrossRef Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37(19):1504–13. doi:10.​1093/​eurheartj/​ehv647.PubMedCrossRef
110.
go back to reference Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, et al. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013;166(6):953–9 e3. doi:10.1016/j.ahj.2013.08.004. Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, et al. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013;166(6):953–9 e3. doi:10.​1016/​j.​ahj.​2013.​08.​004.
111.
go back to reference Gilead Sciences, Inc. Ranolazine prescribing information. 2016. Gilead Sciences, Inc. Ranolazine prescribing information. 2016.
113.
go back to reference Thadani U. Modified-release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction. Am J Cardiovasc Drugs. 2005;5(5):331–4.PubMedCrossRef Thadani U. Modified-release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction. Am J Cardiovasc Drugs. 2005;5(5):331–4.PubMedCrossRef
114.
go back to reference Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med. 2000;29(10):533–8.PubMed Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med. 2000;29(10):533–8.PubMed
115.
go back to reference Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267–74. doi:10.1053/euhj.2001.2896.PubMedCrossRef Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267–74. doi:10.​1053/​euhj.​2001.​2896.PubMedCrossRef
117.
go back to reference Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4(Suppl 4):853–9.PubMedCrossRef Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4(Suppl 4):853–9.PubMedCrossRef
118.
go back to reference Reversible Parkinsonism linked to trimetazidine (continued). Prescrire Int. 2006;15(84):136. Reversible Parkinsonism linked to trimetazidine (continued). Prescrire Int. 2006;15(84):136.
119.
go back to reference Marti Masso JF, Marti I, Carrera N, Poza JJ, Lopez de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–22.PubMedCrossRef Marti Masso JF, Marti I, Carrera N, Poza JJ, Lopez de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–22.PubMedCrossRef
121.
go back to reference European Medicines Agency. European Medicines Agency recommends restricting use of trimetazidine-containing medicines. 22 June 2012. European Medicines Agency. European Medicines Agency recommends restricting use of trimetazidine-containing medicines. 22 June 2012.
122.
123.
go back to reference Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, Lenis J, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol. 2003;42(12):2049–59.PubMedCrossRef Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, Lenis J, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol. 2003;42(12):2049–59.PubMedCrossRef
124.
go back to reference Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. doi:10.1016/S0140-6736(02)09327-3.CrossRef Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. doi:10.​1016/​S0140-6736(02)09327-3.CrossRef
127.
go back to reference Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107(10):1383–9.PubMedCrossRef Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107(10):1383–9.PubMedCrossRef
133.
go back to reference Dunselman PH, van Kempen LH, Bouwens LH, Holwerda KJ, Herweijer AH, Bernink PJ. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol. 1998;81(2):128–32.PubMedCrossRef Dunselman PH, van Kempen LH, Bouwens LH, Holwerda KJ, Herweijer AH, Bernink PJ. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol. 1998;81(2):128–32.PubMedCrossRef
135.
go back to reference Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. Eur J Cardiovasc Prev Rehabil. 2004;11(2):101–12.PubMedCrossRef Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. Eur J Cardiovasc Prev Rehabil. 2004;11(2):101–12.PubMedCrossRef
137.
go back to reference ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349–60. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349–60.
138.
go back to reference Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. doi:10.1016/S0140-6736(09)60503-1.CrossRef Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. doi:10.​1016/​S0140-6736(09)60503-1.CrossRef
139.
go back to reference Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–5.PubMedCrossRef Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–5.PubMedCrossRef
140.
go back to reference Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. doi:10.1056/NEJMoa060989.PubMedCrossRef Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. doi:10.​1056/​NEJMoa060989.PubMedCrossRef
141.
go back to reference LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35. doi:10.1056/NEJMoa050461.PubMedCrossRef LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35. doi:10.​1056/​NEJMoa050461.PubMedCrossRef
142.
go back to reference Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. doi:10.1056/NEJMoa1107579.CrossRef Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. doi:10.​1056/​NEJMoa1107579.CrossRef
143.
go back to reference Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. doi:10.1056/NEJMoa1001282. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. doi:10.​1056/​NEJMoa1001282.
144.
go back to reference Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85. doi:10.1056/NEJMoa1001286. Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85. doi:10.​1056/​NEJMoa1001286.
145.
go back to reference Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. doi:10.1056/NEJMoa1511939. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. doi:10.​1056/​NEJMoa1511939.
146.
147.
go back to reference The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. doi:10.1056/NEJM198706043162301. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. doi:10.​1056/​NEJM198706043162​301.
148.
go back to reference McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–71. doi:10.1016/S0140-6736(03)14283-3.PubMedCrossRef McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–71. doi:10.​1016/​S0140-6736(03)14283-3.PubMedCrossRef
149.
go back to reference Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77. doi:10.1056/NEJM199209033271001.PubMedCrossRef Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77. doi:10.​1056/​NEJM199209033271​001.PubMedCrossRef
151.
go back to reference Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.PubMedCrossRef Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.PubMedCrossRef
152.
go back to reference Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13. doi:10.1016/S0140-6736(03)13800-7.PubMedCrossRef Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13. doi:10.​1016/​S0140-6736(03)13800-7.PubMedCrossRef
Metadata
Title
Drug Therapy for Stable Angina Pectoris
Authors
Talla A. Rousan
Sunil T. Mathew
Udho Thadani
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0691-7

Other articles of this Issue 3/2017

Drugs 3/2017 Go to the issue